Free Trial

Vera Therapeutics (VERA) Stock Price, News & Analysis

Vera Therapeutics logo
$30.61 +0.11 (+0.36%)
As of 11:18 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Vera Therapeutics Stock (NASDAQ:VERA)

Advanced

Key Stats

Today's Range
$30.20
$31.00
50-Day Range
$19.25
$30.94
52-Week Range
$18.53
$51.61
Volume
226,060 shs
Average Volume
1.38 million shs
Market Capitalization
$1.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.00
Consensus Rating
Moderate Buy

Company Overview

Vera Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

VERA MarketRank™: 

Vera Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 500th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 7 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Vera Therapeutics has a consensus price target of $63.00, representing about 106.6% upside from its current price of $30.50.

  • Amount of Analyst Coverage

    Vera Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Vera Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vera Therapeutics is -8.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vera Therapeutics is -8.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vera Therapeutics has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vera Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    19.29% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently increased by 10.38%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Vera Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vera Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.29% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently increased by 10.38%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Vera Therapeutics has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Vera Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    24 people have searched for VERA on MarketBeat in the last 30 days. This is an increase of 380% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vera Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.30% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vera Therapeutics' insider trading history.
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VERA Stock News Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Vera Therapeutics (VERA) Stock Surges 27% Over Last Month
See More Headlines

VERA Stock Analysis - Frequently Asked Questions

Vera Therapeutics' stock was trading at $42.29 on January 1st, 2025. Since then, VERA shares have decreased by 27.9% and is now trading at $30.50.

Vera Therapeutics, Inc. (NASDAQ:VERA) announced its quarterly earnings results on Tuesday, August, 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.38.

Vera Therapeutics (VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO.

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/05/2025
Today
10/09/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERA
CIK
1831828
Fax
N/A
Employees
40
Year Founded
2016

Price Target and Rating

High Price Target
$100.00
Low Price Target
$26.00
Potential Upside/Downside
+105.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$152.15 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-46.70%
Return on Assets
-39.46%

Debt

Debt-to-Equity Ratio
0.16
Current Ratio
17.03
Quick Ratio
17.03

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.08 per share
Price / Book
3.38

Miscellaneous

Outstanding Shares
63,820,000
Free Float
53,421,000
Market Cap
$1.96 billion
Optionable
Optionable
Beta
1.23

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:VERA) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners